bendamustine

Bendamustine is a small molecule antineoplastic agent classified as a nitrogen mustard alkylating agent. It is primarily used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL), particularly in patients who have progressed following rituximab-based therapy. The drug acts by forming electrophilic alkyl groups that covalently bond to DNA, resulting in intra-strand and inter-strand crosslinks, which disrupt DNA function and lead to cell death. This mechanism targets both dividing and quiescent cells, although the precise molecular details remain incompletely understood[1][2][3][4][5]. Bendamustine was originally developed in East Germany during the 1960s.

Brand names

BelrapzoBendekaTreandaVivimustaLevact

Other names

bendamustinaribomustinebendamustinum